Boehringer Ingelheim Pharmaceuticals, Inc.
900 Ridgebury Road
About Boehringer Ingelheim Pharmaceuticals, Inc.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
Value Through Innovation
Our vision of Value through Innovation (VTI) guides our way of working together. It helps us build on our strength and make the most of our distinctive character, enabling us individually and collectively to achieve great success. It also helps us foster value creation throughout our company and to look to the future with constantly renewed commitment and ambition.
Our Lead & Learn principles outline ways in which we can build on our culture of working together to realize and deliver Value through Innovation. These principles encourage us to take risks, ask questions, and seize opportunities in an environment of shared leadership and learning.
Our Success Depends on our People
For more than 125 years, the commitment, innovative-thinking and creative power of our people has made Boehringer Ingelheim one of the fastest growing pharmaceutical companies and an employer of choice. Our workplace reflects our distinctive and innovative culture, built on a foundation of mutual respect and fairness.
We have high expectations and require employees at all levels of the organization to take initiative, stay connected, grow together and achieve outstanding results. To enable this high performance we provide opportunities for personal growth, a collaborative and inclusive work environment and exceptional employee benefits and we reward high achievement with recognition, opportunities and competitive pay.
Driven by a Different Philosophy
We realize that our strength and competitive advantage lie with our people. We support our employees in a number of ways to create a healthy working environment, meaningful work, diversity, mobility, networking and work-life balance.
In a world where business is too often driven by short-term financial goals, Boehringer Ingelheim is truly a company with a different philosophy. As one of the fastest growing pharmaceutical companies in the world, our focus is on helping patients, serving our customers and improving the quality of life for the millions of people who rely on us. Simply put, we remain committed to doing the right thing – for our customers, our communities, our employees and everyone we serve.
Because our products enhance millions of lives, our employees experience the satisfaction of doing important work. Their achievements bring them recognition, and opportunities for career growth. We invite you to join us in improving lives worldwide.
194 articles with Boehringer Ingelheim Pharmaceuticals, Inc.
Research partners from pharma, academia, and SMEs have come together to form the Reward Task Optimisation Consortium.
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
Bridge Biotherapeutics stands to receive up to more than EUR 1.1 billion assuming all milestones are met
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Acquisition adds key platform supporting Boehringer Ingelheim’s focus on patients with difficult-to-treat gastrointestinal and lung cancers
The M&A moves are expected to increase the oncology pipelines of both companies.
Boehringer Ingelheim announced results from two pediatric studies of Pradaxa®, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim focuses on the development of next generation NASH treatments that target all three key drivers of the disease - steatosis, inflammation and fibrosis
The U.S. Food and Drug Administration has granted Fast Track designation to empagliflozin for the reduction of the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure, Boehringer Ingelheim and Eli Lilly and Company announced.
Arizona Care Network Partners with Solve.Care, Pharmaceutical Leader Boehringer Ingelheim To Launch Diabetes Care Administration Network
New Care.Wallet app will help patients proactively address risks and symptoms of diabetes
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Boehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicines
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target from Research Collaboration with Dicerna
Boehringer Ingelheim and Dicerna Pharmaceuticals announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna.
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment
The UPMC Health Plan announced today the initiation of a value-based contract with Boehringer Ingelheim effective 1/1/2019 for Jardiance® (empagliflozin), an oral type 2 diabetes medicine also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
AstraZeneca announced positive results from its Phase III DECLARE-TIMI 58 cardiovascular outcomes clinical trial of Farxiga (dapagliflozin).
CancerLinQ LLC announced today that Integra Connect’s EHR Solution for Oncology has been recognized as the first CancerLinQ® Certified Electronic Health Record (EHR) System.
Boehringer Ingelheim Announces The Launch Of CENTRAGARD™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
Merial, now part of Boehringer Ingelheim, and the maker of HEARTGARD® Plus (ivermectin/pyrantel), the leader in canine heartworm disease prevention, brings heartworm disease prevention and broad-spectrum treatment of intestinal parasites to felines, with new easy-to-use CENTRAGARD.
Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint
Study supports long-term cardiovascular safety of Tradjenta® (linagliptin) in adults with type 2 diabetes
Shares of MabVax Therapeutics have more than doubled this morning after Boehringer Ingelheim inked a deal to acquire the rights to an antibody development program that will be used to target multiple solid tumors.
Platelet Biogenesis (PBG) was awarded a two-year, $3.5 million grant from the U.S. Department of Defense (DoD). The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets.
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in A1C after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10 and 25 mg).
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
New Biologicals Development Center in Biberach, Germany bundles biologics development, increases capacity and expands clinical supply network